Active and passive immunization against Pseudomonas aeruginosa infection of burned patients.
A 16-part polyvalent pseudomonas vaccine, PEV-01 and an immunoglobulin prepared from plasma from human volunteers vaccinated with PEV-01 were tested in a controlled clinical trial in burned patients at Safdarjang hospital, New Delhi. The mortality of the burned patients was reduced four-fold in adults and three-fold in children by the immunological treatments. Both immunoglobulin and vaccine increased the concentration of protective antibody. Patients responded to all 16 components in PEV-01. The vaccine caused no toxic side-effects and enhanced the bactericidal activity of polymorphonuclear leucocytes against Pseudomonas aeruginosa.
D000328:Adult; D001428:Bacterial Vaccines; D001770:Blood Bactericidal Activity; D002056:Burns / Q000150:complications* / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D006801:Humans; D007114:Immunization; D007116:Immunization, Passive; D007223:Infant; D011552:Pseudomonas Infections / Q000276:immunology / Q000517:prevention & control*; D011550:Pseudomonas aeruginosa / Q000276:immunology; D014946:Wound Infection / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*
D001428:Bacterial Vaccines